The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2580-2586

  Rousseaux, Christel ^e   El Jamal, Noura ^a,b,e   Fumery, Mathurin ^a,b   Dubuquoy, Caroline ^e   Romano, Olivier ^a,b   Chatelain, Denis ^c   Langlois, Audrey ^a,b   Bertin, Benjamin ^a,b   Buob, David ^d   Colombel, Jean Frederic ^a,b,d   Cortot, Antoine ^a,b,d   Desreumaux, Pierre ^a,b,d   Dubuquoy, Laurent ^a,b  

^a UNIVERSITÉ DE LILLE   (France)

^b UNIV LILLE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Intestinal Biotech Development ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 5 ACETAMIDOSALICYLIC ACID; AZOXYMETHANE; ETOPOSIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; COLON CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; AZOXYMETHANE; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINES; MALE; MESALAMINE; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, SCID; PPAR GAMMA; TUMOR CELLS, CULTURED;

EID: 84887000015     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt245     Document Type: Article

References (44)

1. Leung,K. et al. (2010) Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest. Endosc., 71, 111-117.
2. Velayos,F.S. et al. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol., 100, 1345-1353.
3. Eaden,J.A. et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535.
4. Brown,W.A. et al. (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci., 45, 1578-1584.
5. Ikeda,I. et al. (2007) 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin. Cancer Res., 13, 6527-6531.
6. Clapper,M.L. et al. (2008) 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis., 14, 1341-1347.
7. Bantel,H. et al. (2000) Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol., 95, 3452-3457.
8. Wahl,C. et al. (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest., 101, 1163-1174.
9. Bos,C.L. et al. (2006) Protein phosphatase 2A is required for mesalazinedependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis, 27, 2371-2382.
10. Campregher,C. et al. (2010) Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin. Cancer Res., 16, 1950-1956.
11. Stolfi,C. et al. (2008) Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis, 29, 1258-1266.
12. Koelink,P.J. et al. (2010) 5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells. Cancer Lett., 287, 82-90.
13. Monteleone,G. et al. (2006) Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ., 13, 202-211.
14. Sarraf,P. et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med., 4, 1046-1052.
15. Rousseaux,C. et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptorgamma. J. Exp. Med., 201, 1205-1215.
16. Grommes,C. et al. (2004) Antineoplastic effects of peroxisome proliferator- activated receptor gamma agonists. Lancet Oncol., 5, 419-429.
17. Osawa,E. et al. (2003) Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology, 124, 361-367.
18. Dubuquoy,L. et al. (2000) Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease. Gastroenterol. Clin. Biol., 24, 719-724.
19. Dubuquoy,L. et al. (2002) Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet, 360, 1410-1418.
20. Staerk Laursen,L. et al. (1990) Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut, 31, 1271-1276.
21. Frieri,G. et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment. Pharmacol. Ther., 13, 1413-1417.
22. Euhus,D.M. et al. (1986) Tumor measurement in the nude mouse. J. Surg. Oncol., 31, 229-234.
23. Papanikolaou,A. et al. (1998) Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett., 130, 29-34.
24. Ahmadi,A. et al. (2009) Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J. Gastroenterol., 15, 61-66.
25. Rubin,D.T. et al. (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm. Bowel Dis., 14, 265-274.
26. Rubin,D.T. et al. (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin. Gastroenterol. Hepatol., 4, 1346-1350.
27. Stolfi,C. et al. (2012) Colorectal cancer chemoprevention by mesalazine and its derivatives. J. Biomed. Biotechnol., 2012, 980458.
28. Stolfi,C. et al. (2008) Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem. Pharmacol., 75, 668-676.
29. Reinacher-Schick,A. et al. (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis, 24, 443-451.
30. Chan,T.A. et al. (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA, 95, 681-686.
31. Schwab,M. et al. (2008) PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis, 29, 1407-1414.
32. Chu,E.C. et al. (2007) Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment. Pharmacol. Ther., 25, 1443-1449.
33. Tanaka,T. et al. (2001) Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res., 61, 2424-2428.
34. Koelink,P.J. et al. (2009) 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model. Carcinogenesis, 30, 1217-1224.
35. Lefebvre,A.M. et al. (1998) Activation of the peroxisome proliferatoractivated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med., 4, 1053-1057.
36. Saez,E. et al. (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med., 4, 1058-1061.
37. Girnun,G.D. et al. (2002) APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl Acad. Sci. USA, 99, 13771-13776.
38. Kulke,M.H. et al. (2002) A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J., 8, 395-399.
39. Dubuquoy,L. et al. (2003) Impaired expression of peroxisome proliferatoractivated receptor gamma in ulcerative colitis. Gastroenterology, 124, 1265-1276.
40. Eaden,J. et al. (2000) Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther., 14, 145-153.
41. van Staa,T.P. et al. (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 54, 1573-1578.
42. Nguyen,G.C. et al. (2012) 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of nonreferral populations. Am. J. Gastroenterol., 107, 1298-1304.
43. Bernstein,C.N. et al. (2003) Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am. J. Gastroenterol., 98, 2784-2788.
44. Terdiman,J.P. et al. (2007) 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm. Bowel Dis., 13, 367-371.